These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

572 related articles for article (PubMed ID: 25009275)

  • 1. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
    Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
    J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-α-synuclein immunotherapy reduces α-synuclein propagation in the axon and degeneration in a combined viral vector and transgenic model of synucleinopathy.
    Spencer B; Valera E; Rockenstein E; Overk C; Mante M; Adame A; Zago W; Seubert P; Barbour R; Schenk D; Games D; Rissman RA; Masliah E
    Acta Neuropathol Commun; 2017 Jan; 5(1):7. PubMed ID: 28086964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
    El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
    Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axonopathy in an α-synuclein transgenic model of Lewy body disease is associated with extensive accumulation of C-terminal-truncated α-synuclein.
    Games D; Seubert P; Rockenstein E; Patrick C; Trejo M; Ubhi K; Ettle B; Ghassemiam M; Barbour R; Schenk D; Nuber S; Masliah E
    Am J Pathol; 2013 Mar; 182(3):940-53. PubMed ID: 23313024
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy targeting toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating α-synuclein transmission and neuroinflammation.
    Kim C; Spencer B; Rockenstein E; Yamakado H; Mante M; Adame A; Fields JA; Masliah D; Iba M; Lee HJ; Rissman RA; Lee SJ; Masliah E
    Mol Neurodegener; 2018 Aug; 13(1):43. PubMed ID: 30092810
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Passive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body disease.
    Masliah E; Rockenstein E; Mante M; Crews L; Spencer B; Adame A; Patrick C; Trejo M; Ubhi K; Rohn TT; Mueller-Steiner S; Seubert P; Barbour R; McConlogue L; Buttini M; Games D; Schenk D
    PLoS One; 2011 Apr; 6(4):e19338. PubMed ID: 21559417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Naturally occurring autoantibodies against α-synuclein rescues memory and motor deficits and attenuates α-synuclein pathology in mouse model of Parkinson's disease.
    Huang YR; Xie XX; Ji M; Yu XL; Zhu J; Zhang LX; Liu XG; Wei C; Li G; Liu RT
    Neurobiol Dis; 2019 Apr; 124():202-217. PubMed ID: 30481547
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Α-synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration.
    Tran HT; Chung CH; Iba M; Zhang B; Trojanowski JQ; Luk KC; Lee VM
    Cell Rep; 2014 Jun; 7(6):2054-65. PubMed ID: 24931606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
    Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
    Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation and characterization of novel conformation-specific monoclonal antibodies for α-synuclein pathology.
    Vaikath NN; Majbour NK; Paleologou KE; Ardah MT; van Dam E; van de Berg WD; Forrest SL; Parkkinen L; Gai WP; Hattori N; Takanashi M; Lee SJ; Mann DM; Imai Y; Halliday GM; Li JY; El-Agnaf OM
    Neurobiol Dis; 2015 Jul; 79():81-99. PubMed ID: 25937088
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission.
    Bae EJ; Lee HJ; Rockenstein E; Ho DH; Park EB; Yang NY; Desplats P; Masliah E; Lee SJ
    J Neurosci; 2012 Sep; 32(39):13454-69. PubMed ID: 23015436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Active Humoral and Cellular Immunization Approaches for the Treatment of Synucleinopathies.
    Rockenstein E; Ostroff G; Dikengil F; Rus F; Mante M; Florio J; Adame A; Trinh I; Kim C; Overk C; Masliah E; Rissman RA
    J Neurosci; 2018 Jan; 38(4):1000-1014. PubMed ID: 29246926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy with an antibody against CD1d modulates neuroinflammation in an α-synuclein transgenic model of Lewy body like disease.
    Iba M; Kwon S; Kim C; Szabo M; Horan-Portelance L; Lopez-Ocasio M; Dagur P; Overk C; Rissman RA; Masliah E
    J Neuroinflammation; 2024 Apr; 21(1):93. PubMed ID: 38622654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal live imaging of retinal α-synuclein::GFP deposits in a transgenic mouse model of Parkinson's Disease/Dementia with Lewy Bodies.
    Price DL; Rockenstein E; Mante M; Adame A; Overk C; Spencer B; Duong-Polk KX; Bonhaus D; Lindsey J; Masliah E
    Sci Rep; 2016 Jul; 6():29523. PubMed ID: 27389831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of MultiTEP-Platform-Based Recombinant Protein Vaccine, PV-1950R, Targeting Three B-Cell Antigenic Determinants of Pathological α-Synuclein.
    Zagorski K; Chailyan G; Hovakimyan A; Antonyan T; Kiani Shabestari S; Petrushina I; Davtyan H; Cribbs DH; Blurton-Jones M; Masliah E; Agadjanyan MG; Ghochikyan A
    Int J Mol Sci; 2022 May; 23(11):. PubMed ID: 35682759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Novel Calpain Inhibitors in Transgenic Animal Model of Parkinson's disease/dementia with Lewy bodies.
    Hassen GW; Kesner L; Stracher A; Shulman A; Rockenstein E; Mante M; Adame A; Overk C; Rissman RA; Masliah E
    Sci Rep; 2018 Dec; 8(1):18083. PubMed ID: 30591714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress of immunotherapy of anti-α-synuclein in Parkinson's disease.
    Wang Z; Gao G; Duan C; Yang H
    Biomed Pharmacother; 2019 Jul; 115():108843. PubMed ID: 31055236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroinflammation is associated with infiltration of T cells in Lewy body disease and α-synuclein transgenic models.
    Iba M; Kim C; Sallin M; Kwon S; Verma A; Overk C; Rissman RA; Sen R; Sen JM; Masliah E
    J Neuroinflammation; 2020 Jul; 17(1):214. PubMed ID: 32680537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation.
    Dufty BM; Warner LR; Hou ST; Jiang SX; Gomez-Isla T; Leenhouts KM; Oxford JT; Feany MB; Masliah E; Rohn TT
    Am J Pathol; 2007 May; 170(5):1725-38. PubMed ID: 17456777
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Dutta AK; Armstrong C; Luo D; Das B; Spencer B; Rissman RA
    ACS Chem Neurosci; 2023 Mar; 14(5):885-896. PubMed ID: 36749600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.